The rise and fall of the atypical antipsychotics
Author:
Open Access
- 1 October 2011
- journal article
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 199 (4) , 266-268
Abstract
Summary: The antipsychotics brought hope and optimism to people with schizophrenia and to those who care for them. There have been successive classes of antipsychotics used by the pharmaceutical industry to persuade doctors and patients that ‘new’ is better. Evidence is growing that the primary purpose of these fabricated classes is for marketing. It is time we stopped using these expensive labels – they are all just antipsychotics.Keywords
This publication has 14 references indexed in Scilit:
- From Evidence-based Medicine to Marketing-based Medicine: Evidence from Internal Industry DocumentsJournal of Bioethical Inquiry, 2010
- Second-generation antipsychotics for schizophrenia: can we resolve the conflict?Psychological Medicine, 2009
- Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysisThe Lancet, 2009
- Selective Publication of Antidepressant Trials and Its Influence on Apparent EfficacyNew England Journal of Medicine, 2008
- Effectiveness of Antipsychotic Drugs in Patients with Chronic SchizophreniaNew England Journal of Medicine, 2005
- Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished dataThe Lancet, 2004
- The Creation of Psychopharmacology2002
- Clozapine: back to the future for schizophrenia researchThe Lancet, 1995
- The history of clozapinePsychopharmacology, 1989
- Effect of Chlorpromazine on the Behaviour of Chronically Overactive Psychotic PatientsBMJ, 1954